Review of angiogenesis in hepatocellular carcinoma

被引:122
作者
Muto, Jun [1 ]
Shirabe, Ken [1 ]
Sugimachi, Keishi [2 ]
Maehara, Yoshihiko [1 ]
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka 8128582, Japan
[2] Kyushu Univ Hosp, Beppu Hosp, Dept Surg, Beppu, Oita, Japan
关键词
angiogenesis; arteriogenesis; hepatocellular carcinoma; ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE INHIBITORS; CHRONIC LIVER-DISEASE; FACTOR MESSENGER-RNA; IN-VIVO; PROGNOSTIC-SIGNIFICANCE; HEPATIC RESECTION; ANGIOPOIETIN-2; DISPLAYS; CLINICAL-SIGNIFICANCE; TUMOR ANGIOGENESIS;
D O I
10.1111/hepr.12310
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
Hepatocellular carcinoma (HCC) is a hypervascular tumor, and its vascularity is unique and greatly different from peripheral parenchyma of liver. Afferent and efferent vessels of HCC lesions come to differ as the lesion develops. The characteristic of the flow regulates the common style of metastasis. The portal tract of the HCC lesion is the first site of the intrahepatic metastasis, because cancer cells roll into the portal vein via efferent flow. On microscopic observation, HCC displays marked vascular abnormalities, arteriogenesis and capillarization. Arteriogenesis is defined as the growth of functional collateral arteries covered with smooth muscle cells from pre-existing arteries. Sinusoidal capillarization involves the transformation of fenestrated hepatic sinusoids into continuous capillaries. Several angiogenic factors have been reported, and some of them are studied as prognostic factors or target molecules of chemotherapeutic reagents. However, the mechanism of neovascularization during HCC development is still unclear. This review discusses the characteristics of angiogenesis in HCC and known angiogenic factors of HCC.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 102 条
[1]
Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor [J].
Albert, DH ;
Tapang, P ;
Magoc, TJ ;
Pease, LJ ;
Reuter, DR ;
Wei, RQ ;
Li, JL ;
Guo, J ;
Bousquet, PF ;
Ghoreishi-Haack, NS ;
Wang, B ;
Bukofzer, GT ;
Wang, YC ;
Stavropoulos, JA ;
Hartandi, K ;
Niquette, AL ;
Soni, N ;
Johnson, EF ;
McCall, JO ;
Bouska, JJ ;
Luo, Y ;
Donawho, CK ;
Dai, YJ ;
Marcotte, PA ;
Glaser, KB ;
Michaelides, MR ;
Davidsen, SK .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (04) :995-1006
[2]
Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005 [J].
Altekruse, Sean F. ;
McGlynn, Katherine A. ;
Reichman, Marsha E. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1485-1491
[3]
Clinicopathological features of hepatocellular carcinoma evaluated by vascular endothelial growth factor expression [J].
Amaoka, Nozomi ;
Osada, Shinji ;
Kanematsu, Masayuki ;
Imai, Hisashi ;
Tomita, Hiroyuki ;
Tokuyama, Yasuharu ;
Sakashita, Fumio ;
Nonaka, Kennichi ;
Goshima, Satoshi ;
Kondo, Hiroshi ;
Adachi, Yosuke .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 22 (12) :2202-2207
[4]
Angiogenesis in chronic liver disease [J].
Amarapurkar, Anjali D. ;
Amarapurkar, Deepak N. ;
Vibhav, S. ;
Patel, Nikhil D. .
ANNALS OF HEPATOLOGY, 2007, 6 (03) :170-173
[5]
Role of tyrosine kinase inhibitors in cancer therapy [J].
Arora, A ;
Scholar, EM .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (03) :971-979
[6]
Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system [J].
Augustin, Hellmut G. ;
Koh, Gou Young ;
Thurston, Gavin ;
Alitalo, Kari .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2009, 10 (03) :165-177
[7]
Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor [J].
Bhide, RS ;
Cai, ZW ;
Zhang, YZ ;
Qian, LG ;
Wei, D ;
Barbosa, S ;
Lombardo, LJ ;
Borzilleri, RM ;
Zheng, XP ;
Wu, LI ;
Barrish, JC ;
Kim, SH ;
Leavitt, K ;
Mathur, A ;
Leith, L ;
Chao, S ;
Wautlet, B ;
Mortillo, S ;
Jeyaseelan, R ;
Kukral, D ;
Hunt, JT ;
Kamath, A ;
Fura, A ;
Vyas, V ;
Marathe, P ;
D'Arienzo, C ;
Derbin, G ;
Fargnoli, J .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (07) :2143-2146
[8]
Angiogenesis in cancer and other diseases [J].
Carmeliet, P ;
Jain, RK .
NATURE, 2000, 407 (6801) :249-257
[9]
Hepatocellular carcinoma: Current management and future trends [J].
Carr, BI .
GASTROENTEROLOGY, 2004, 127 (05) :S218-S224
[10]
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models [J].
Chang, Yong S. ;
Adnane, Jalila ;
Trail, Pamela A. ;
Levy, Joan ;
Henderson, Arris ;
Xue, Dahai ;
Bortolon, Elizabeth ;
Ichetovkin, Marina ;
Chen, Charles ;
McNabola, Angela ;
Wilkie, Dean ;
Carter, Christopher A. ;
Taylor, Ian C. A. ;
Lynch, Mark ;
Wilhelm, Scott .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (05) :561-574